Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01243944 |
|
Recruitment Status :
Completed
First Posted : November 19, 2010
Results First Posted : March 6, 2015
Last Update Posted : March 6, 2019
|
Sponsor:
Incyte Corporation
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Polycythemia Vera | Drug: ruxolitinib tablets Other: Best Available Therapy (BAT) | Phase 3 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 222 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial) |
| Actual Study Start Date : | October 27, 2010 |
| Actual Primary Completion Date : | January 15, 2014 |
| Actual Study Completion Date : | February 9, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Polycythemia vera
MedlinePlus related topics:
Safety
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ruxolitinib tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
|
Drug: ruxolitinib tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy |
|
Best Available Therapy
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
|
Other: Best Available Therapy (BAT)
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Other Names:
|
Primary Outcome Measures :
- The Percentage of Participants Achieving a Primary Response at Week 32 [ Time Frame: 32 Weeks ]Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).
Secondary Outcome Measures :
- The Percentage of Participants Achieving a Durable Primary Response at Week 48 [ Time Frame: 48 Weeks ]Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.
- The Percentage of Participants Achieving Complete Hematological Remission at Week 32 [ Time Frame: 32 Weeks ]Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10^9/L and a white blood cell count less than or equal to 10 X 10^9/L.
- The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48 [ Time Frame: 48 Weeks ]Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.
- The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48 [ Time Frame: 48 Weeks ]Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.
- The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48 [ Time Frame: 48 Weeks ]Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.
- Estimated Duration of the Primary Response [ Time Frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study ]
Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).
Kaplan-Meier estimates are provided for duration of primary response.
- The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32 [ Time Frame: 32 Weeks ]Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.
- The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48 [ Time Frame: 48 Weeks ]Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.
- Estimated Duration of the Complete Hematological Remission [ Time Frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study ]
Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).
Kaplan-Meier estimates are provided for duration of complete hematological remission.
- Duration of the Absence of Phlebotomy Eligibility [ Time Frame: 256 Weeks ]Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.
- Duration of Reduction in Spleen Volume [ Time Frame: 256 Weeks ]Duration of spleen volume reduction is defined as the time from the first occurrence of a >=35% reduction from baseline in spleen volume until the date of the first documented progression.
- Duration of The Overall Clinicohematologic Response [ Time Frame: 256 Weeks ]Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria
- Participants resistant to or intolerant of hydroxyurea
- Participants with a phlebotomy requirement
- Participants with splenomegaly (palpable or non-palpable) and a spleen volume, as measured by MRI (or CT in applicable participants ), of greater than or equal to 450 cubic centimeters
- Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion Criteria:
- Women who are pregnant or nursing
- Participants with inadequate liver or renal function
- Participants with significant bacterial, fungal, parasitic, or viral infection requiring treatment
- Participants with an active malignancy within the past 5 years, excluding specific skin cancers
- Participants with known active hepatitis or HIV positivity
- Participants who have previously received treatment with a JAK inhibitor
- Participants being treated with any investigational agent
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01243944
Locations
Show 102 study locations
Sponsors and Collaborators
Incyte Corporation
Novartis Pharmaceuticals
Investigators
| Study Director: | Srdan Verstovsek, MD,PhD | M.D. Anderson Cancer Center | |
| Study Director: | Mark Jones, MD | Incyte Corporation |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Incyte Corporation |
| ClinicalTrials.gov Identifier: | NCT01243944 |
| Other Study ID Numbers: |
CINC424B2301 |
| First Posted: | November 19, 2010 Key Record Dates |
| Results First Posted: | March 6, 2015 |
| Last Update Posted: | March 6, 2019 |
| Last Verified: | February 2019 |
Keywords provided by Incyte Corporation:
|
INCB018424 |
Additional relevant MeSH terms:
|
Polycythemia Vera Polycythemia Hematologic Diseases Bone Marrow Neoplasms Hematologic Neoplasms Neoplasms by Site Neoplasms Bone Marrow Diseases Myeloproliferative Disorders Lenalidomide Pomalidomide Hydroxyurea Pipobroman Anagrelide Immunologic Factors |
Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Antineoplastic Agents Antisickling Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Fibrinolytic Agents Fibrin Modulating Agents Platelet Aggregation Inhibitors Antineoplastic Agents, Alkylating Alkylating Agents |